Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with …
NASDAQ: CHRS– We recommended investors buy Coherus a few weeks ago under the IPO price when it was trading around $13.10.
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a $28 price target, …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a $28 price …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a price target of …
In a research note released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals Inc. (CNCE) with a $28.